Want to see EVFM full AI Analyst Report?
EVFM Stock Chart & Stats
$0.01
<$0.01(13.89%)
At close: 4:00 PM EDT
$0.01
<$0.01(13.89%)
Day’s Range― - ―
52-Week Range<$0.01 - $0.02
Previous CloseN/A
Volume198.22K
Average Volume (3M)479.42K
Market Cap
$993.98K
Enterprise Value$60.16
Total Cash (Recent Filing)$285.00K
Total Debt (Recent Filing)$68.50M
Price to Earnings (P/E)―
Beta-0.04
Next Earnings
Nov 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding132,530,080
10 Day Avg. Volume708,277
30 Day Avg. Volume479,419
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)-0.02
Price to Sales (P/S)0.06
P/FCF Ratio-0.59
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)57.5
Revenue Forecast (FY)$241.13M
Bulls Say, Bears Say
Bulls Say
Strong Gross MarginA gross margin of about 71% indicates that Phexxi generates substantial value after direct product costs. If maintained, this provides a foundation for covering operating expenses, supporting commercialization investments, and improving earnings potential as revenue scale and manufacturing economics develop.
Expanded Phexxi Manufacturing CapacityAdding Zhaoke as a second Phexxi producer broadens the manufacturing footprint and reduces reliance on the existing source. Subject to regulatory approval, greater capacity and lower unit costs could support U.S. and international demand while strengthening the product’s commercial economics.
Cash-burn ImprovementAlthough cash flow remains below breakeven, the sharp reduction in operating and free-cash-flow losses versus 2021–2023 shows meaningful progress in cash management. Continued improvement could reduce financing dependence and move the business closer to becoming self-funding over time.
Bears Say
Declining RevenueA revenue decline of roughly 23.8% signals weakening recent commercial performance and makes it harder to absorb the company’s operating cost base. Persistent contraction could limit investment capacity, weaken negotiating leverage, and delay the benefits expected from expanded Phexxi production.
Negative Equity And Elevated LeveragePersistently negative equity combined with sizable debt and a comparatively small asset base materially restricts financial flexibility. This structure increases refinancing and solvency risk, limits the ability to fund growth internally, and leaves less capacity to absorb operating setbacks.
Severe Profitability DeteriorationThe shift from a small 2025 profit to approximately a -100% TTM net margin shows that current revenue is not covering the broader operating model. Negative operating earnings may prolong cash needs, constrain reinvestment, and prevent the strong gross margin from translating into sustainable profitability.
Evofem Biosciences News
EVFM FAQ
What was Evofem Biosciences’s price range in the past 12 months?
Evofem Biosciences lowest stock price was <$0.01 and its highest was $0.02 in the past 12 months.
What is Evofem Biosciences’s market cap?
Evofem Biosciences’s market cap is $993.98K.
When is Evofem Biosciences’s upcoming earnings report date?
Evofem Biosciences’s upcoming earnings report date is Nov 12, 2026 which is in 42 days.
How were Evofem Biosciences’s earnings last quarter?
Evofem Biosciences released its earnings results on Aug 19, 2026. The company reported -$0.081 earnings per share for the quarter.
Is Evofem Biosciences overvalued?
According to Wall Street analysts Evofem Biosciences’s price is currently Overvalued.
Does Evofem Biosciences pay dividends?
Evofem Biosciences does not currently pay dividends.
What is Evofem Biosciences’s EPS estimate?
Evofem Biosciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Evofem Biosciences have?
Evofem Biosciences has 132,530,080 shares outstanding.
What happened to Evofem Biosciences’s price movement after its last earnings report?
Evofem Biosciences reported an EPS of -$0.081 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Evofem Biosciences?
Currently, no hedge funds are holding shares in EVFM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Evofem Biosciences
Evofem Biosciences, Inc. operates as a biopharmaceutical enterprise dedicated to innovating and bringing to market treatments that address critical underserved areas in women's sexual and reproductive health. Their leading commercial offering is Phexxi, a vaginal gel specifically designed as a contraceptive. Additionally, the company is actively advancing EVO100, an antimicrobial vaginal gel under development, intended to prevent the urogenital spread of both Chlamydia trachomatis and Neisseria gonorrhoeae infections in women. The company's main office is situated in San Diego, California.